表紙:非アルコール性脂肪性肝疾患(NAFLD)および非アルコール性脂肪性肝炎(NASH)の世界市場の分析 (2021年~2031年):疾患の原因別、薬剤タイプ別、販売チャネル別の予測、主要国の分析、主要企業、新型コロナウイルス感染症 (COVID-19) からの回復シナリオ
市場調査レポート
商品コード
1001276

非アルコール性脂肪性肝疾患(NAFLD)および非アルコール性脂肪性肝炎(NASH)の世界市場の分析 (2021年~2031年):疾患の原因別、薬剤タイプ別、販売チャネル別の予測、主要国の分析、主要企業、新型コロナウイルス感染症 (COVID-19) からの回復シナリオ

Non-alcoholic Fatty Liver Disease (NAFLD) & NASH Market Report 2021-2031: Forecasts by Disease Cause, by Drug Type, by Sales Channel, Regional & Leading National Market Analysis, Leading NAFLD & NASH Companies, and COVID-19 Recovery Scenarios

出版日: | 発行: Visiongain Ltd | ページ情報: 英文 338 Pages | 納期: 即日から翌営業日

価格
価格表記: GBPを日本円(税抜)に換算
本日の銀行送金レート: 1GBP=153.58円

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

非アルコール性脂肪性肝疾患(NAFLD)および非アルコール性脂肪性肝炎(NASH)の世界市場の分析 (2021年~2031年):疾患の原因別、薬剤タイプ別、販売チャネル別の予測、主要国の分析、主要企業、新型コロナウイルス感染症 (COVID-19) からの回復シナリオ
出版日: 2021年02月17日
発行: Visiongain Ltd
ページ情報: 英文 338 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の非アルコール性脂肪性肝疾患(NAFLD)および非アルコール性脂肪性肝炎(NASH)市場について分析し、製品の概要や市場の基本構造・最新情勢、主な成長・抑制要因、市場規模の推定値・予測値 (2031年まで)、疾患の原因別、薬剤タイプ別、販売チャネル別および地域別・主要国の詳細動向、主要企業のプロファイル、COVID-19の影響と回復シナリオ (V字型/U字型/W字型/L字型) などについて、体系的な情報を提供しています。

目次

第1章 レポートの概要

第2章 エグゼクティブサマリー

  • 主なハイライト

第3章 業界の概要

  • 概要
    • NAFLDおよびNASHの危険因子
    • NAFLD / NASHの診断と病期分類
    • 脂肪症の画像評価
    • NAFLDの肝生検
    • 臨床診療におけるNAFLDの診断と病期分類への実用的なアプローチ
  • COVID-19の肝疾患に対する影響

第4章 市場の成長要因、抑制要因、機会

  • 概要
  • NASHの影響を受ける患者数の増加
  • ヘルスケア費の上昇
  • 注目の研究と医薬品開発
  • 低コストで確実な診断方法の欠如
  • 規制機関と医薬品承認による課題
  • ポーターのファイブフォース分析
    • 新規参入者の脅威-低
    • 売り手の交渉力-低度
    • 買い手の交渉力-中度
    • 代替品の脅威-中から低度
    • 競争企業間の敵対関係-高度

第5章 世界市場分析

  • 世界の市場概要
  • 世界の市場の推計・予測
    • COVID前の市場分析
    • COVID後の市場分析(V、W、U、L字型の回復)
  • 地域市場分析
    • COVID前の市場分析
    • 市場シェア分析、2021年、2026年、2031年(%)
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • 病気の原因別市場の内訳
    • COVID前の市場分析
    • 市場シェア分析、2021年、2026年、2031年(%)
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • 医薬品タイプ別市場の内訳
    • COVID前の市場分析
    • 市場シェア分析、2021年、2026年、2031年(%)
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • 販売チャネル別市場の内訳
    • COVID前の市場分析
    • 市場シェア分析、2021年、2026年、2031年(%)
    • COVID後の影響市場分析(V、W、U、L字型の回復)

第6章 北米市場分析

  • 北米市場概要
  • 北米市場の推計・予測
    • COVID前の市場分析
    • COVID後の市場分析(V、W、U、L字型の回復)
  • 国別市場の内訳
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • 病気の原因別市場の内訳
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • 薬剤タイプ別北米の市場の内訳
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • 販売チャネル別市場の内訳
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • 米国市場分析
    • 米国市場の見通し
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • カナダ市場分析
    • カナダ市場の見通し
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)

第7章 欧州市場分析

  • 欧州市場概要
  • 欧州市場の推計・予測
    • COVID前の市場分析
    • COVID後の市場分析(V、W、U、L字型の回復)
  • 国別市場の内訳
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • 病気の原因別市場の内訳
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • 薬剤タイプ別市場の内訳
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • 販売チャネル別市場の内訳
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • ドイツ市場分析
    • ドイツ市場の見通し
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • 英国市場分析
    • 英国市場の見通し
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • フランス市場分析
    • フランス市場の見通し
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • イタリア市場分析
    • イタリア市場の見通し
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • スペイン市場分析
    • スペイン市場の見通し
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • その他欧州市場分析
    • その他欧州市場の見通し
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)

第8章 アジア太平洋地域市場分析

  • アジア太平洋地域市場概要
  • アジア太平洋地域市場の推計・予測
    • COVID前の市場分析
    • COVID後の市場分析(V、W、U、L字型の回復)
  • 国別市場の内訳
    • COVID前の市場分析
    • 市場シェア分析、2021年、2026年、2031年(%)
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • 病気の原因別市場の内訳
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • 薬剤タイプ別市場の内訳
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • 販売チャネル別市場の内訳
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • 中国市場分析
    • 中国市場の見通し
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • インド市場分析
    • インド市場の見通し
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • 日本市場分析
    • 日本市場の見通し
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • 韓国市場分析
    • 韓国市場の見通し
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • オーストラリア市場分析
    • オーストラリア市場の見通し
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • その他アジア太平洋地域の市場分析
    • その他アジア太平洋地域市場の見通し
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)

第9章 LAMEA市場分析

  • LAMEA市場概要
  • LAMEA市場の推計・予測
    • COVID前の市場分析
    • COVID後の市場分析(V、W、U、L字型の回復)
  • 国別市場の内訳
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • 病気の原因別市場の内訳
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • 薬剤タイプ別市場の内訳
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • 販売チャネル別市場の内訳
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • ブラジル市場分析
    • ブラジル市場の見通し
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • サウジアラビア市場分析
    • サウジアラビア市場の見通し
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • 南アフリカ市場分析
    • 南アフリカ市場の見通し
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • メキシコ市場分析
    • メキシコ市場の見通し
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • アラブ首長国連邦市場分析
    • UAE市場の見通し
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)
  • その他のLAMEA市場分析
    • その他のLAMEA市場の見通し
    • COVID前の市場分析
    • COVID後の影響市場分析(V、W、U、L字型の回復)

第10章 主要企業のプロファイル

  • Pfizer Inc Company
    • 企業のスナップショット
    • 企業概要
    • 企業の財務プロファイル
    • 企業の製品のベンチマーク
    • 企業の最新動向
  • F. Hoffmann-La Roche Ltd Company
    • 企業のスナップショット
    • 企業概要
    • 企業の財務プロファイル
    • 企業の製品のベンチマーク
    • 企業の最新動向
  • Takeda Pharmaceuticals Company
    • 企業のスナップショット
    • 企業概要
    • 企業の財務プロファイル
    • 企業の製品のベンチマーク
    • 企業の最新動向
  • Intercept Pharmaceuticals、Inc。Company
    • 企業のスナップショット
    • 企業概要
    • 企業の財務プロファイル
    • 企業の製品のベンチマーク
  • AstraZeneca Pharmaceuticals Company
    • 企業のスナップショット
    • 企業概要
    • 企業の財務プロファイル
    • 企業の製品のベンチマーク
    • 企業の最新動向
  • Novartis Pharmaceutical Company
    • 企業のスナップショット
    • 企業概要
    • 企業の財務プロファイル
    • 企業の製品のベンチマーク
    • 企業の最新動向
  • Merck & Co. Company
    • 企業のスナップショット
    • 企業概要
    • 企業の財務プロファイル
    • 企業の製品のベンチマーク
    • 企業の最新動向
  • AbbVie Inc Company
    • 企業のスナップショット
    • 企業概要
    • 企業の財務プロファイル
    • 企業の製品のベンチマーク
    • 企業の最新動向
  • Gilead Science Inc Company
    • 企業のスナップショット
    • 企業概要
    • 企業の財務プロファイル
    • 企業の製品のベンチマーク
    • 企業の最新動向
  • Genfit Biotechnology Company
    • 企業のスナップショット
    • 企業概要
    • 企業の財務プロファイル
    • 企業の製品のベンチマーク
    • 企業の最新動向
  • Cardax Inc Pharmaceutical Company
    • 企業のスナップショット
    • 企業概要
    • 企業の財務プロファイル
    • 企業の製品のベンチマーク
  • Daewoong Co Ltd Company
    • 企業のスナップショット
    • 企業概要
    • 企業の財務プロファイル
    • 企業の製品のベンチマーク
    • 企業の最新動向
  • Madrigal Pharmaceuticals、Inc Company
    • 企業のスナップショット
    • 企業概要
    • 企業の製品のベンチマーク
  • Mirum Pharmaceuticals Inc Company
    • 企業のスナップショット
    • 企業概要
    • 企業の最新動向
  • GW Pharmaceuticals Company
    • 企業のスナップショット
    • 企業概要
    • 企業の財務プロファイル
    • 企業の製品のベンチマーク
    • 企業の最新動向

第11章 結論と提言

  • 市場シェア分析、2021年、2026年、2031年(%)

第12章 用語集

図表

List of Tables

  • Table 1. Global Non-alcoholic Fatty Liver Disease & NASH Market Forecast, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 2. Global Non-alcoholic Fatty Liver Disease & NASH Market Snapshot, 2021 & 2031 (US$billion, CAGR %)
  • Table 3. Risk factors for NAFLD & NASH
  • Table 4. Global Non-alcoholic Fatty Liver Disease & NASH Market Forecast, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 5. Global Non-alcoholic Fatty Liver Disease & NASH Market Forecast, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 6. Global Non-alcoholic Fatty Liver Disease & NASH Market Forecast, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 7. Global Non-alcoholic Fatty Liver Disease & NASH Market Forecast, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 8. Global Non-alcoholic Fatty Liver Disease & NASH Market Forecast, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 9. Global Non-alcoholic Fatty Liver Disease & NASH Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 10. Global Non-alcoholic Fatty Liver Disease & NASH Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 11. Global Non-alcoholic Fatty Liver Disease & NASH Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 12. Global Non-alcoholic Fatty Liver Disease & NASH Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 13. Global Non-alcoholic Fatty Liver Disease & NASH Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 14. Global Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 15. Global Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 16. Global Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 17. Global Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 18. Global Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 19. Global Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 20. Global Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 21. Global Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 22. Global Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 23. Global Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 24. Global Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 25. Global Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 26. Global Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 27. Global Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 28. Global Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 29. North America Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 30. North America Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 31. North America Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 32. North America Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 33. North America Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 34. North America Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 35. North America Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 36. North America Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 37. North America Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 38. North America Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 39. North America Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 40. North America Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 41. North America Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 42. North America Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 43. North America Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 44. North America Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 45. North America Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 46. North America Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 47. North America Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 48. North America Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 49. US Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 50. US Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 51. US Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 52. US Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 53. US Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 54. Canada Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 55. Canada Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 56. Canada Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 57. Canada Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 58. Canada Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 59. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 60. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 61. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 62. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 63. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 64. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 65. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 66. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 67. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 68. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 69. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 70. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 71. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 72. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 73. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 74. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 75. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 76. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 77. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 78. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 79. Germany Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 80. Germany Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 81. Germany Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 82. Germany Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 83. Germany Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 84. UK Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 85. UK Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 86. UK Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 87. UK Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 88. UK Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 89. France Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 90. France Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 91. France Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 92. France Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 93. France Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 94. Italy Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 95. Italy Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 96. Italy Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 97. Italy Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 98. Italy Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 99. Spain Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 100. Spain Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 101. Spain Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 102. Spain Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 103. Spain Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 104. Rest of Europe Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 105. Rest of Europe Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 106. Rest of Europe Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 107. Rest of Europe Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 108. Rest of Europe Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 109. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 110. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 111. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 112. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 113. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 114. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 115. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 116. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 117. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 118. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 119. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 120. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 121. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 122. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 123. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 124. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 125. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 126. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 127. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 128. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 129. China Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 130. China Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 131. China Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 132. China Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 133. China Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 134. India Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 135. India Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 136. India Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 137. India Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 138. India Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 139. Japan Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 140. Japan Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 141. Japan Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 142. Japan Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 143. Japan Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 144. South Korea Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 145. South Korea Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 146. South Korea Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 147. South Korea Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 148. South Korea Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 149. Australia Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 150. Australia Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 151. Australia Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 152. Australia Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 153. Australia Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 154. Rest of Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 155. Rest of Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 156. Rest of Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 157. Rest of Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 158. Rest of Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 159. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 160. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 161. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 162. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 163. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 164. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 165. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 166. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 167. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 168. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 169. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 170. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 171. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 172. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 173. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 174. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 175. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 176. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 177. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 178. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 179. Brazil Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 180. Brazil Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 181. Brazil Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 182. Brazil Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 183. Brazil Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 184. Saudi Arabia Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 185. Saudi Arabia Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 186. Saudi Arabia Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 187. Saudi Arabia Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 188. Saudi Arabia Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 189. South Africa Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 190. South Africa Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 191. South Africa Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 192. South Africa Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 193. South Africa Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 194. Mexico Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 195. Mexico Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 196. Mexico Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 197. Mexico Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 198. Mexico Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 199. UAE Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 200. UAE Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 201. UAE Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 202. UAE Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 203. UAE Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 204. Rest of LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
  • Table 205. Rest of LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery)
  • Table 206. Rest of LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery)
  • Table 207. Rest of LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery)
  • Table 208. Rest of LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery)
  • Table 209. Pfizer Inc: Company Information
  • Table 210. Pfizer Inc: Company Revenue 2015-2019 (US$ Million, AGR %)
  • Table 211. Pfizer Inc: Company Product and Service Benchmarking
  • Table 212. Pfizer Inc: Company Product Pipeline
  • Table 213. Pfizer Inc: Company Recent Developments till December,2020
  • Table 214. F. Hoffmann-La Roche Ltd: Company Information
  • Table 215. F. Hoffmann-La Roche Ltd: Company Revenue 2015-2019 (US$ Million, AGR %)
  • Table 216. F. Hoffmann-La Roche Ltd: Company Product and Service Benchmarking
  • Table 217. F. Hoffmann-La Roche Ltd: Company Product Pipeline
  • Table 218. F. Hoffmann-La Roche Ltd: Company Recent Developments till December,2020
  • Table 219. Takeda Pharmaceuticals: Company Information
  • Table 220. Takeda Pharmaceuticals: Company Revenue 2015-2019 (US$ Million, AGR %)
  • Table 221. Takeda Pharmaceuticals: Company Product and Service Benchmarking
  • Table 222. Takeda Pharmaceuticals: Company Product Pipeline
  • Table 223. Takeda Pharmaceuticals: Company Recent Developments till December,2020
  • Table 224. Intercept Pharmaceuticals, Inc.: Company Information
  • Table 225. Intercept Pharmaceuticals, Inc.: Company Revenue 2015-2019 (US$ Million, AGR %)
  • Table 226. Intercept Pharmaceuticals, Inc.: Company Product and Service Benchmarking
  • Table 227. F. Hoffmann-La Roche Ltd: Company Product Pipeline
  • Table 228. AstraZeneca Pharmaceuticals: Company Information
  • Table 229. AstraZeneca Pharmaceuticals: Company Revenue 2015-2019 (US$ Million, AGR %)
  • Table 230. AstraZeneca Pharmaceuticals: Company Product and Service Benchmarking
  • Table 231. AstraZeneca Pharmaceuticals: Company Recent Developments till December,2020
  • Table 232. AstraZeneca Pharmaceuticals: Company Recent Developments till December,2020
  • Table 233. Novartis AG: Company Information
  • Table 234. Novartis AG: Company Revenue 2015-2019 (US$ Million, AGR %)
  • Table 235. Novartis AG: Company Product and Service Benchmarking
  • Table 236. Novartis AG: Company Recent Developments till December,2020
  • Table 237. Novartis AG: Company Recent Developments till December,2020
  • Table 238. Merck & Co. Inc: Company Information
  • Table 239. Merck & Co., Inc: Company Revenue 2015-2019 (US$ Million, AGR %)
  • Table 240. Merck & Co., Inc: Company Product and Service Benchmarking
  • Table 241. Merck & Co., Inc: Company Recent Developments till December,2020
  • Table 242. Merck & Co., Inc: Company Recent Developments till December,2020
  • Table 243. AbbVie Inc: Company Information
  • Table 244. AbbVie Inc: Company Revenue 2015-2019 (US$ Million, AGR %)
  • Table 245. AbbVie Inc: Company Product and Service Benchmarking
  • Table 246. AbbVie Inc: Company Recent Developments till December,2020
  • Table 247. AbbVie Inc: Company Recent Developments till December,2020
  • Table 248. Gilead Science Inc: Company Information
  • Table 249. Gilead Sciences, Inc.: Company Revenue 2015-2019 (US$ Million, AGR %)
  • Table 250. Gilead Sciences, Inc.: Company Product and Service Benchmarking
  • Table 251. Gilead Sciences, Inc.: Company Recent Developments till December,2020
  • Table 252. Gilead Sciences, Inc.: Company Recent Developments till December,2020
  • Table 253. Genfit Biotechnology: Company Information
  • Table 254. Genfit Biotechnology: Company Revenue 2015-2019 (US$ Million, AGR %)
  • Table 255. Genfit Biotechnology: Company Product and Service Benchmarking
  • Table 256. Genfit Biotechnology: Company Recent Developments till December,2020
  • Table 257. Cardax Inc Pharmaceutical: Company Information
  • Table 258. Cardax Inc Pharmaceutical: Company Revenue 2015-2019 (US$ Million, AGR %)
  • Table 259. Cardax Inc Pharmaceutical: Company Product and Service Benchmarking
  • Table 260. Cardax Inc Pharmaceutical: Company Recent Developments till December,2020
  • Table 261. Daewoong Co Ltd: Company Information
  • Table 262. Daewoong Co Ltd: Company Revenue 2015-2019 (US$ Million, AGR %)
  • Table 263. Daewoong Co Ltd: Company Product and Service Benchmarking
  • Table 264. Daewoong Co Ltd: Company Recent Developments till December,2020
  • Table 265. Daewoong Co Ltd: Company Recent Developments till December,2020
  • Table 266. Madrigal Pharmaceuticals, Inc: Company Information
  • Table 267. Madrigal Pharmaceuticals, Inc: Company Recent Developments till December,2020
  • Table 268. Mirum Pharmaceuticals, Inc: Company Information
  • Table 269. Mirum Pharmaceuticals, Inc.: Company Recent Developments till December,2020
  • Table 270. Mirum Pharmaceuticals, Inc.: Company Recent Developments till December,2020
  • Table 271. GW Pharmaceuticals Plc: Company Information
  • Table 272. GW Pharmaceuticals Plc: Company Revenue 2015-2019 (US$ Million, AGR %)
  • Table 273. GW Pharmaceuticals Plc: Company Product and Service Benchmarking
  • Table 274. GW Pharmaceuticals Plc: Company Recent Developments till December,2020
  • Table 275. GW Pharmaceuticals Plc: Company Recent Developments till December,2020

List of Figures

  • Figure 1. Global Non-alcoholic Fatty Liver Disease & NASH Market Forecast, 2021-2031 (US$ Billion, AGR (%))
  • Figure 2. Global Non-alcoholic Fatty Liver Disease & NASH Market Segmentation
  • Figure 3. Global Non-alcoholic Fatty Liver Disease & NASH Market Forecast, 2021-2031 (US$ Billion, AGR (%))
  • Figure 4. Global Non-alcoholic Fatty Liver Disease & NASH Market Forecast, 2021-2031 (US$ Billion, AGR (%))
  • Figure 5. Global Non-alcoholic Fatty Liver Disease & NASH Market Forecast, 2021-2031 (US$ Billion, AGR (%)) (V-Shaped Recovery)
  • Figure 6. Global Non-alcoholic Fatty Liver Disease & NASH Market Forecast, 2021-2031 (US$ Billion, AGR (%)) (W-Shaped Recovery)
  • Figure 7. Global Non-alcoholic Fatty Liver Disease & NASH Market Forecast, 2021-2031 (US$ Billion, AGR (%)) (U-Shaped Recovery)
  • Figure 8. Global Non-alcoholic Fatty Liver Disease & NASH Market Forecast, 2021-2031 (US$ Billion, AGR (%)) (L-Shaped Recovery)
  • Figure 9. Global Non-alcoholic Fatty Liver Disease & NASH Market by Region, 2021-2031 (US$ Billion, AGR (%))
  • Figure 10. Global Non-alcoholic Fatty Liver Disease & NASH Market Share Forecast by Region 2021, 2026, 2031 (%)
  • Figure 11. Global Non-alcoholic Fatty Liver Disease & NASH Market by Region, 2021-2031 (US$ Billion, AGR (%)) (V-Shaped Recovery)
  • Figure 12. Global Non-alcoholic Fatty Liver Disease & NASH Market by Region, 2021-2031 (US$ Billion, AGR (%)) (W-Shaped Recovery)
  • Figure 13. Global Non-alcoholic Fatty Liver Disease & NASH Market by Region, 2021-2031 (US$ Billion, AGR (%)) (U-Shaped Recovery)
  • Figure 14. Global Non-alcoholic Fatty Liver Disease & NASH Market by Region, 2021-2031 (US$ Billion, AGR (%)) (L-Shaped Recovery)
  • Figure 15. Global Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (US$ Billion, AGR (%))
  • Figure 16. Global Non-alcoholic Fatty Liver Disease & NASH Market Share Forecast by Disease Cause 2021, 2026, 2031 (%)
  • Figure 17. Global Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (US$ Billion, AGR (%)) (V-Shaped Recovery)
  • Figure 18. Global Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (US$ Billion, AGR (%)) (W-Shaped Recovery)
  • Figure 19. Global Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (US$ Billion, AGR (%)) (U-Shaped Recovery)
  • Figure 20. Global Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (US$ Billion, AGR (%)) (L-Shaped Recovery)
  • Figure 21. Global Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (US$ Billion, AGR (%))
  • Figure 22. Global Non-alcoholic Fatty Liver Disease & NASH Market Share Forecast by Drug Type 2021, 2026, 2031 (%)
  • Figure 23. Global Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (US$ Billion, AGR (%)) (V-Shaped Recovery)
  • Figure 24. Global Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (US$ Billion, AGR (%)) (W-Shaped Recovery)
  • Figure 25. Global Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (US$ Billion, AGR (%)) (U-Shaped Recovery)
  • Figure 26. Global Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (US$ Billion, AGR (%)) (L-Shaped Recovery)
  • Figure 27. Global Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (US$ Billion, AGR (%))
  • Figure 28. Global Non-alcoholic Fatty Liver Disease & NASH Market Share Forecast by Sales Channel 2021, 2026, 2031 (%)
  • Figure 29. Global Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (US$ Billion, AGR (%)) (V-Shaped Recovery)
  • Figure 30. Global Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (US$ Billion, AGR (%)) (W-Shaped Recovery)
  • Figure 31. Global Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (US$ Billion, AGR (%)) (U-Shaped Recovery)
  • Figure 32. Global Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (US$ Billion, AGR (%)) (L-Shaped Recovery)
  • Figure 33. North America Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (US$ Billion, AGR (%))
  • Figure 34. North America Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (US$ Billion, AGR (%)) (V-Shaped Recovery)
  • Figure 35. North America Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (US$ Billion, AGR (%)) (W-Shaped Recovery)
  • Figure 36. North America Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (US$ Billion, AGR (%)) (U-Shaped Recovery)
  • Figure 37. North America Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (US$ Billion, AGR (%)) (L-Shaped Recovery)
  • Figure 38. North America Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (US$ Billion, AGR (%))
  • Figure 39. North America Non-alcoholic Fatty Liver Disease & NASH Market Share Forecast by Country 2021, 2026, 2031 (%)
  • Figure 40. North America Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (US$ Billion, AGR (%)) (V-Shaped Recovery)
  • Figure 41. North America Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (US$ Billion, AGR (%)) (W-Shaped Recovery)
  • Figure 42. North America Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (US$ Billion, AGR (%)) (U-Shaped Recovery)
  • Figure 43. North America Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (US$ Billion, AGR (%)) (L-Shaped Recovery)
  • Figure 44. North America Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (US$ Billion, AGR (%))
  • Figure 45. North America Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (US$ Billion, AGR (%)) (V-Shaped Recovery)
  • Figure 46. North America Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (US$ Billion, AGR (%)) (W-Shaped Recovery)
  • Figure 47. North America Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (US$ Billion, AGR (%)) (U-Shaped Recovery)
  • Figure 48. North America Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (US$ Billion, AGR (%)) (L-Shaped Recovery)
  • Figure 49. North America Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (US$ Billion, AGR (%))
  • Figure 50. North America Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (US$ Billion, AGR (%)) (V-Shaped Recovery)
  • Figure 51. North America Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (US$ Billion, AGR (%)) (W-Shaped Recovery)
  • Figure 52. North America Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (US$ Billion, AGR (%)) (U-Shaped Recovery)
  • Figure 53. North America Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (US$ Billion, AGR (%)) (L-Shaped Recovery)
  • Figure 54. North America Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (US$ Billion, AGR (%))
  • Figure 55. North America Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (US$ Billion, AGR (%)) (V-Shaped Recovery)
  • Figure 56. North America Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (US$ Billion, AGR (%)) (W-Shaped Recovery)
  • Figure 57. North America Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (US$ Billion, AGR (%)) (U-Shaped Recovery)
  • Figure 58. North America Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (US$ Billion, AGR (%)) (L-Shaped Recovery)
  • Figure 59. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (US$ Billion, AGR (%))
  • Figure 60. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (US$ Billion, AGR (%)) (V-Shaped Recovery)
  • Figure 61. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (US$ Billion, AGR (%)) (W-Shaped Recovery)
  • Figure 62. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (US$ Billion, AGR (%)) (U-Shaped Recovery)
  • Figure 63. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (US$ Billion, AGR (%)) (L-Shaped Recovery)
  • Figure 64. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (US$ Billion, AGR (%))
  • Figure 65. Europe Non-alcoholic Fatty Liver Disease & NASH Market Share Forecast by Country 2021, 2026, 2031 (%)
  • Figure 66. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (US$ Billion, AGR (%)) (V-Shaped Recovery)
  • Figure 67. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (US$ Billion, AGR (%)) (W-Shaped Recovery)
  • Figure 68. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (US$ Billion, AGR (%)) (U-Shaped Recovery)
  • Figure 69. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (US$ Billion, AGR (%)) (L-Shaped Recovery)
  • Figure 70. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (US$ Billion, AGR (%))
  • Figure 71. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (US$ Billion, AGR (%)) (V-Shaped Recovery)
  • Figure 72. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (US$ Billion, AGR (%)) (W-Shaped Recovery)
  • Figure 73. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (US$ Billion, AGR (%)) (U-Shaped Recovery)
  • Figure 74. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (US$ Billion, AGR (%)) (L-Shaped Recovery)
  • Figure 75. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (US$ Billion, AGR (%))
  • Figure 76. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (US$ Billion, AGR (%)) (V-Shaped Recovery)
  • Figure 77. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (US$ Billion, AGR (%)) (W-Shaped Recovery)
  • Figure 78. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (US$ Billion, AGR (%)) (U-Shaped Recovery)
  • Figure 79. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (US$ Billion, AGR (%)) (L-Shaped Recovery)
  • Figure 80. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (US$ Billion, AGR (%))
  • Figure 81. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (US$ Billion, AGR (%)) (V-Shaped Recovery)
  • Figure 82. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (US$ Billion, AGR (%)) (W-Shaped Recovery)
  • Figure 83. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (US$ Billion, AGR (%)) (U-Shaped Recovery)
  • Figure 84. Europe Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (US$ Billion, AGR (%)) (L-Shaped Recovery)
  • Figure 85. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (US$ Billion, AGR (%))
  • Figure 86. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (US$ Billion, AGR (%)) (V-Shaped Recovery)
  • Figure 87. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (US$ Billion, AGR (%)) (W-Shaped Recovery)
  • Figure 88. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (US$ Billion, AGR (%)) (U-Shaped Recovery)
  • Figure 89. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (US$ Billion, AGR (%)) (L-Shaped Recovery)
  • Figure 90. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (US$ Billion, AGR (%))
  • Figure 91. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market Share Forecast by Country 2021, 2026, 2031 (%)
  • Figure 92. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (US$ Billion, AGR (%)) (V-Shaped Recovery)
  • Figure 93. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (US$ Billion, AGR (%)) (W-Shaped Recovery)
  • Figure 94. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (US$ Billion, AGR (%)) (U-Shaped Recovery)
  • Figure 95. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (US$ Billion, AGR (%)) (L-Shaped Recovery)
  • Figure 96. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (US$ Billion, AGR (%))
  • Figure 97. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (US$ Billion, AGR (%)) (V-Shaped Recovery)
  • Figure 98. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (US$ Billion, AGR (%)) (W-Shaped Recovery)
  • Figure 99. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (US$ Billion, AGR (%)) (U-Shaped Recovery)
  • Figure 100. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (US$ Billion, AGR (%)) (L-Shaped Recovery)
  • Figure 101. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (US$ Billion, AGR (%))
  • Figure 102. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (US$ Billion, AGR (%)) (V-Shaped Recovery)
  • Figure 103. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (US$ Billion, AGR (%)) (W-Shaped Recovery)
  • Figure 104. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (US$ Billion, AGR (%)) (U-Shaped Recovery)
  • Figure 105. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (US$ Billion, AGR (%)) (L-Shaped Recovery)
  • Figure 106. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (US$ Billion, AGR (%))
  • Figure 107. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (US$ Billion, AGR (%)) (V-Shaped Recovery)
  • Figure 108. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (US$ Billion, AGR (%)) (W-Shaped Recovery)
  • Figure 109. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (US$ Billion, AGR (%)) (U-Shaped Recovery)
  • Figure 110. Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (US$ Billion, AGR (%)) (L-Shaped Recovery)
  • Figure 111. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (US$ Billion, AGR (%))
  • Figure 112. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (US$ Billion, AGR (%)) (V-Shaped Recovery)
  • Figure 113. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (US$ Billion, AGR (%)) (W-Shaped Recovery)
  • Figure 114. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (US$ Billion, AGR (%)) (U-Shaped Recovery)
  • Figure 115. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Value, 2021-2031 (US$ Billion, AGR (%)) (L-Shaped Recovery)
  • Figure 116. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (US$ Billion, AGR (%))
  • Figure 117. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market Share Forecast by Country 2021, 2026, 2031 (%)
  • Figure 118. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (US$ Billion, AGR (%)) (V-Shaped Recovery)
  • Figure 119. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (US$ Billion, AGR (%)) (W-Shaped Recovery)
  • Figure 120. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (US$ Billion, AGR (%)) (U-Shaped Recovery)
  • Figure 121. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Country, 2021-2031 (US$ Billion, AGR (%)) (L-Shaped Recovery)
  • Figure 122. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (US$ Billion, AGR (%))
  • Figure 123. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (US$ Billion, AGR (%)) (V-Shaped Recovery)
  • Figure 124. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (US$ Billion, AGR (%)) (W-Shaped Recovery)
  • Figure 125. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (US$ Billion, AGR (%)) (U-Shaped Recovery)
  • Figure 126. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause, 2021-2031 (US$ Billion, AGR (%)) (L-Shaped Recovery)
  • Figure 127. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (US$ Billion, AGR (%))
  • Figure 128. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (US$ Billion, AGR (%)) (V-Shaped Recovery)
  • Figure 129. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (US$ Billion, AGR (%)) (W-Shaped Recovery)
  • Figure 130. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (US$ Billion, AGR (%)) (U-Shaped Recovery)
  • Figure 131. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type, 2021-2031 (US$ Billion, AGR (%)) (L-Shaped Recovery)
  • Figure 132. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (US$ Billion, AGR (%))
  • Figure 133. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (US$ Billion, AGR (%)) (V-Shaped Recovery)
  • Figure 134. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (US$ Billion, AGR (%)) (W-Shaped Recovery)
  • Figure 135. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (US$ Billion, AGR (%)) (U-Shaped Recovery)
  • Figure 136. LAMEA Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel, 2021-2031 (US$ Billion, AGR (%)) (L-Shaped Recovery)
  • Figure 137. Pfizer Inc: Company Revenue 2015-2019 (US$ Million, AGR %)
  • Figure 138. Pfizer Inc: Company Operating Income 2015-2019 (US$ Million, AGR %)
  • Figure 139. Pfizer Inc: Company EBITDA 2015-2019 (US$ Million, AGR %)
  • Figure 140. Pfizer Inc: Company Net Income/Loss 2015-2019 (US$ Million, AGR %)
  • Figure 141. F. Hoffmann-La Roche Ltd: Company Revenue 2015-2019 (US$ Million, AGR %)
  • Figure 142. F. Hoffmann-La Roche Ltd: Company Operating Income 2015-2019 (US$ Million, AGR %)
  • Figure 143. F. Hoffmann-La Roche Ltd: Company EBITDA 2015-2019 (US$ Million, AGR %)
  • Figure 144. F. Hoffmann-La Roche Ltd: Company Net Income/Loss 2015-2019 (US$ Million, AGR %)
  • Figure 145. Takeda Pharmaceuticals: Company Revenue 2015-2019 (US$ Million, AGR %)
  • Figure 146. Takeda Pharmaceuticals: Company Operating Income 2015-2019 (US$ Million, AGR %)
  • Figure 147. Takeda Pharmaceuticals: Company EBITDA 2015-2019 (US$ Million, AGR %)
  • Figure 148. Takeda Pharmaceuticals: Company Net Income/Loss 2015-2019 (US$ Million, AGR %)
  • Figure 149. Intercept Pharmaceuticals, Inc.: Company Revenue 2015-2019 (US$ Million, AGR %)
  • Figure 150. Intercept Pharmaceuticals, Inc.: Company Operating Income 2015-2019 (US$ Million, AGR %)
  • Figure 151. Intercept Pharmaceuticals, Inc.: Company EBITDA 2015-2019 (US$ Million, AGR %)
  • Figure 152. Intercept Pharmaceuticals, Inc.: Company Net Income/Loss 2015-2019 (US$ Million, AGR %)
  • Figure 153. AstraZeneca Pharmaceuticals: Company Revenue 2015-2019 (US$ Million, AGR %)
  • Figure 154. AstraZeneca Pharmaceuticals: Company Operating Income 2015-2019 (US$ Million, AGR %)
  • Figure 155. AstraZeneca Pharmaceuticals: Company EBITDA 2015-2019 (US$ Million, AGR %)
  • Figure 156. AstraZeneca Pharmaceuticals: Company Net Income/Loss 2015-2019 (US$ Million, AGR %)
  • Figure 157. Novartis AG: Company Revenue 2015-2019 (US$ Million, AGR %)
  • Figure 158. Novartis AG: Company Operating Income 2015-2019 (US$ Million, AGR %)
  • Figure 159. Novartis AG: Company EBITDA 2015-2019 (US$ Million, AGR %)
  • Figure 160. Novartis AG: Company Net Income/Loss 2015-2019 (US$ Million, AGR %)
  • Figure 161. Merck & Co., Inc: Company Revenue 2015-2019 (US$ Million, AGR %)
  • Figure 162. Merck & Co., Inc: Company Operating Income 2015-2019 (US$ Million, AGR %)
  • Figure 163. Merck & Co., Inc: Company EBITDA 2015-2019 (US$ Million, AGR %)
  • Figure 164. Merck & Co., Inc: Company Net Income/Loss 2015-2019 (US$ Million, AGR %)
  • Figure 165. AbbVie Inc: Company Revenue 2015-2019 (US$ Million, AGR %)
  • Figure 166. AbbVie Inc: Company Operating Income 2015-2019 (US$ Million, AGR %)
  • Figure 167. AbbVie Inc: Company EBITDA 2015-2019 (US$ Million, AGR %)
  • Figure 168. AbbVie Inc: Company Net Income/Loss 2015-2019 (US$ Million, AGR %)
  • Figure 169. Gilead Sciences, Inc.: Company Revenue 2015-2019 (US$ Million, AGR %)
  • Figure 170. Gilead Sciences, Inc.: Company Operating Income 2015-2019 (US$ Million, AGR %)
  • Figure 171. Gilead Sciences, Inc.: Company EBITDA 2015-2019 (US$ Million, AGR %)
  • Figure 172. Gilead Sciences, Inc.: Company Net Income/Loss 2015-2019 (US$ Million, AGR %)
  • Figure 173. Genfit Biotechnology: Company Revenue 2015-2019 (US$ Million, AGR %)
  • Figure 174. Genfit Biotechnology: Company Operating Income 2015-2019 (US$ Million, AGR %)
  • Figure 175. Genfit Biotechnology: Company EBITDA 2015-2019 (US$ Million, AGR %)
  • Figure 176. Genfit Biotechnology: Company Net Income/Loss 2015-2019 (US$ Million, AGR %)
  • Figure 177. Cardax Inc Pharmaceutical: Company Revenue 2015-2019 (US$ Million, AGR %)
  • Figure 178. Cardax Inc Pharmaceutical: Company Operating Income 2015-2019 (US$ Million, AGR %)
  • Figure 179. Cardax Inc Pharmaceutical: Company EBITDA 2015-2019 (US$ Million, AGR %)
  • Figure 180. Cardax Inc Pharmaceutical: Company Net Income/Loss 2015-2019 (US$ Million, AGR %)
  • Figure 181. Daewoong Co Ltd: Company Revenue 2015-2019 (US$ Million, AGR %)
  • Figure 182. Daewoong Co Ltd: Company Operating Income 2015-2019 (US$ Million, AGR %)
  • Figure 183. Daewoong Co Ltd: Company EBITDA 2015-2019 (US$ Million, AGR %)
  • Figure 184. Daewoong Co Ltd: Company Net Income/Loss 2015-2019 (US$ Million, AGR %)
  • Figure 185. Madrigal Pharmaceuticals, Inc: Company Operating Income 2015-2019 (US$ Million, AGR %)
  • Figure 186. Madrigal Pharmaceuticals, Inc: Company EBITDA 2015-2019 (US$ Million, AGR %)
  • Figure 187. Madrigal Pharmaceuticals, Inc: Company Net Income/Loss 2015-2019 (US$ Million, AGR %)
  • Figure 188. GW Pharmaceuticals Plc: Company Revenue 2015-2019 (US$ Million, AGR %)
  • Figure 189. GW Pharmaceuticals Plc: Company Operating Income 2015-2019 (US$ Million, AGR %)
  • Figure 190. GW Pharmaceuticals Plc: Company EBITDA 2015-2019 (US$ Million, AGR %)
  • Figure 191. GW Pharmaceuticals Plc: Company Net Income/Loss 2015-2019 (US$ Million, AGR %

List of Companies Profiled

  • AbbVie Inc. (AbbVie)
  • AstraZeneca PLC
  • Cardax, Inc.
  • Daewoong Co Ltd
  • Genfit Biotechnology
  • Gilead Sciences, Inc.
  • GW Pharmaceuticals plc.
  • Intercept Pharmaceuticals, Inc.
  • Madrigal Pharmaceuticals, Inc.,
  • Merck & Co., Inc.
  • Mirum Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc. (Pfizer)
  • Roche Holding AG (Roche)
  • Takeda Pharmaceutical Company Limited
  • List of Other Companies
  • Accinov
  • ActoGeniX
  • Aju IB Investment
  • Ally Bridge Group
  • Amrita Therapeutics
  • AOBiome, LLC
  • AquaBounty Technologies
  • Arctic Aurora Life Science
  • Assembly Biosciences
  • Azitra
  • BaseClear
  • Bio-Technology General
  • BIOASTER
  • Biological & Popular Culture, Inc.
  • BiomX
  • Bioverativ Therapeutics
  • Blue Turtle Bio
  • Bristol-Myers Squibb
  • BYTC Corp
  • C3J Therapeutics
  • Caelus Health
  • Cd4 Biosciences, Inc.
  • Cedars-Sinai Medical Centre
  • Chengdu Sen Nuo Wei Biotechnology Co., Ltd
  • CLI Ventures
  • Codexis Laboratories Hungary Kft
  • CoreBiome
  • Crestovo
  • CRS Bio, Inc
  • DayTwo
  • Effective Pharmaceuticals, Inc.
  • Enterome Bioscience
  • Enterome SA
  • EnviroFlight, LLC
  • Epibiome.
  • Epitope Pharmaceuticals, Inc.
  • Evelo Biosciences
  • Evolve BioSystems
  • Ferring Pharmaceuticals
  • Ferring Sas
  • Finch Therapeutics
  • Finch Therapeutics Group, Inc.
  • Genomatix Ltd.
  • Genten Therapeutics, Inc
  • GenVec, Inc.
  • Global Bioscience Company
  • GT Biologics Limited
  • Hartlab LLC
  • Harvest Capital Strategies, LLC
  • HealthMine, Inc
  • IBBL
  • iCarbonX
  • Igen Biotech Group
  • ImmuneBiotech AB
  • Immuron, Ltd.
  • INC Research
  • Intrexon Actobiotics N.V.
  • Intrexon Energy Partners II, LLC
  • Janssen Biotech
  • Kallyope
  • Leading Biosciences
  • LNC Therapeutics
  • Lundbeckfond Ventures
  • MaaT Pharma SA
  • MatriSys Bioscience
  • Microbiome Therapeutics, LLC
  • Microbiomics Limited
  • Mirna Therapeutics
  • Nitrocell
  • NIZO
  • Nubiyota
  • NuMe Health LLC
  • Okanagan Specialty Fruits Inc.
  • Omnes Capital
  • OpenBiome
  • OptiBiotix Health plc
  • OrbiMed HealthCare Fund Management
  • Osel, Inc.
  • OvaXon, LLC
  • Oxitec
  • Symbiotix Biotherapies
  • Synlogic, Inc.
  • Synthetic Biologics, Inc.
  • Synthetic Genomics, Inc.
  • TargEDys
  • Tech Coast Angels (TCA)
  • The Microbiota Company Limited
  • Trans Ova Genetics LC
  • Tucana Health Limited
  • Vedanta Biosciences Inc.
  • Veristat
  • Vertex Pharmaceuticals Inc.
  • Whole Biome
  • Xycrobe Therapeutics

List of Organizations Mentioned in the Report

  • Alimentary Pharmabiotic Centre
  • APC Microbiome Institute
  • Center
  • Central Drugs Standard Control Organisation (CDSCO)
  • French National Institute for Agricultural Research
  • Hadasit Medical Research Services & Development Ltd
  • Hadassah Medical Center
  • Health Canada
  • Institut National de la Recherche Agronomique
  • John Theurer Cancer Center of Hackensack Meridian Health
  • King's College London
  • La Trobe University
  • Lawrence Berkeley National Laboratory
  • Leiden University Medical Center
  • Mayo clinic
  • Medical University of Graz
  • Medicines and Healthcare products Regulatory Agency (MHRA)
  • Medicines Control Council (MCC)
  • Memorial Sloan Kettering Cancer Center
  • Microbiome Institute at University College Cork
  • Ministry of Health, Labour and Welfare (MHLW)
  • Monash University
  • Murdoch Children Research Institute
  • National Institute of Allergy and Infectious Diseases
  • NYU Langone Health
  • Orange Country Research Center
  • Pan American Health Organization (PAHO)
  • Ruprecht-Karls-University Heidelberg
  • Saudi Food and Drug Authority (SFDA)
  • St. Joseph's Hamilton
  • Stanford Cancer Institute
  • The Endocrine Society
  • The Parker Institute for Cancer Immunotherapy
  • Therapeutic Goods Administration (TGA)
  • University of British Columbia
  • University of California
  • University of Melbourne
  • University of Minnesota
  • University of Nebraska
  • University of Pennsylvania
  • University of South Alabama (USA) Mitchell Cancer Institut
  • University of Texas at Austin
  • University of Texas MD Anderson Cancer Roswell Park Comprehensive Cancer Center
  • University of Tokyo
  • USA Mitchell Cancer Center
  • World Health Organization (WHO)
  • World Intellectual Property Organization WIPO
  • World Trade Organization (WTO)
目次
Product Code: PHA1074

Title:
Non-alcoholic Fatty Liver Disease (NAFLD) & NASH Market Report 2021-2031
Forecasts by Disease Cause (Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity, Other Disease Causes), by Drug Type (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cencicriviroc, Other Drug Type), by Sales Channel (Hospital Pharmacy, Online Suppliers, Retail Pharmacy, Other Sales Channel) AND Regional and Leading National Market Analysis PLUS Analysis of Leading NAFLD & NASH Companies AND COVID-19 Recovery Scenarios.

What is holding you back in the Non-alcoholic Fatty Liver Disease & NASH Business?

NASH is presently diagnosed by methods such as blood test, imaging or a liver biopsy. These tests are time consuming and have less certainty as they are generic tests. Imaging techniques like CT, MRI and Ultrasound scans were inaccurate to diagnose NASH. These tests are not just incorrect for NASH diagnosis but also cost a lot. This absence of conclusive diagnostic methods in order to detect NASH, is the major challenge to the NASH market.

Our 330+ page report provides 275 tables, 191 charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing non-alcoholic fatty liver disease & NASH market. Buy our report to see how to exploit these opportunities in the global market.

Forecasts to 2031 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), Porter's Five Forces Analysis, product profiles and commercial developments.

Discover sales predictions for the global non-alcoholic fatty liver disease & NASH market and submarkets

Along with revenue prediction for the overall world market, there are 5 segmentations of the non-alcoholic fatty liver disease & NASH market, with forecasts for 5 Disease Cause, 5 Drug Types, 3 Types, 4 Sales Channel each forecasted at a global, regional, and country level, along with COVID-19 impact recovery pattern analysis for all segments.

Leading companies and the potential for market growth

As per Visiongain analysis, global non-alcoholic fatty liver disease & NASH market is estimated to be valued at US$xx billion in 2021 and is projected to reach at a market value of US$xx billion by 2031. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.

What all Segments Are Covered in the Report?

Global Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause (COVID-19 Impact Recovery Analysis Covered)

  • Hypertension
  • Heart Disease
  • High Blood Lipid
  • Type 2 Diabetes
  • Obesity
  • Other Disease Causes

Global Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type (COVID-19 Impact Recovery Analysis Covered)

  • Vitamin E & Pioglitazone
  • Ocaliva
  • Elafibranor
  • Selonsertib
  • Cencicriviroc
  • Other Drug Type

Global Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel (COVID-19 Impact Recovery Analysis Covered)

  • Hospital Pharmacy
  • Online Suppliers
  • Retail Pharmacy
  • Other Sales Channel

Global Non-alcoholic Fatty Liver Disease & NASH Market by Region (COVID-19 Impact Recovery Analysis Covered)

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East
  • Africa

Which Key Players Are Leading the Global Market and how much Share do they Hold?

The global market for non-alcoholic fatty liver disease & NASH is ascending and has made significant gains in NASH treatments. The players in the non-alcoholic fatty liver disease & NASH market are striving to tap the opportunities that this market offers.

Companies are trying to explore the available prospects by adopting various strategies such as:

  • Mergers and acquisitions.
  • Product launches.
  • Collaborations and partnerships.

Product approval is a major milestone facing all key competitors in the non-alcoholic fatty liver disease & NASH market. Several strategies were implemented by key market players between 2015 and Jan 2021. There are over 100 pharma companies involved in different aspects of NASH therapeutics, including drugs, diagnostics, biomarkers, services, analyses and others.

How the Non-alcoholic Fatty Liver Disease & NASH Market report helps you? Buy this report to find answers for below questions and how can help you to stay updated

  • What is the current size of the overall global non-alcoholic fatty liver disease & NASH market? How much will this market be worth from 2021 to 2031?
  • How will market shares of the leading national markets change by 2031, and which geographical region will lead the market in 2031?
  • Who are the leading companies and what are their activities, results, developments and prospects?
  • What are some of the most prominent human non-alcoholic fatty liver disease & NASH currently in development?
  • What are the main trends that will affect the world non-alcoholic fatty liver disease & NASH market between 2021 and 2031?
  • What are the main strengths, weaknesses, opportunities and threats for the market?
  • What are the social, technological, economic and political influences that will shape that industry over the next ten years?
  • How will the global non-alcoholic fatty liver disease & NASH market evolve over the forecasted period, 2021 to 2031?
  • Which NASH drugs and therapies can succeed and what revenues could they generate to 2031?
  • What will be the main commercial drivers for the NASH market from 2021 to 2031?
  • How will market shares of prominent national markets change from 2021, and which countries will lead the market in 2031, achieving highest revenues and fastest growth?
  • How will that industry evolve between 2021 and 2031, especially in R&D?

Top 20 Leading Players Profiled in the Report:

  • Pfizer Inc. (Pfizer)
  • Roche Holding AG (Roche)
  • Takeda Pharmaceutical Company Limited
  • Intercept Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Novartis AG
  • Merck & Co., Inc.
  • AbbVie Inc. (AbbVie)
  • Gilead Sciences, Inc.
  • Genfit Biotechnology
  • Cardax, Inc.
  • Daewoong Co Ltd
  • Madrigal Pharmaceuticals, Inc.,
  • Mirum Pharmaceuticals, Inc.
  • GW Pharmaceuticals plc.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Non-alcoholic Fatty Liver Disease & NASH Market and leading companies. You will find data, trends and predictions.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Introduction to Non-alcoholic Fatty Liver Disease & NASH Market
  • 1.2 Non-alcoholic Fatty Liver Disease & NASH Market Definition
  • 1.3 Global Market Overview
  • 1.4 Why You Should Read This Report
  • 1.5 What This Report Delivers
  • 1.6 Key Questions Answered By This Analytical Report Include:
  • 1.7 Who is This Report For?
  • 1.8 Methodology
    • 1.8.1 Primary Research
    • 1.8.2 Secondary Research
    • 1.8.3 Market Evaluation & Forecasting Methodology
  • 1.9 Frequently Asked Questions (FAQs)
  • 1.10 Associated Visiongain Reports
  • 1.11 About Visiongain

2 Executive Summary

  • 2.1 Key Highlights

3 Non-alcoholic Fatty Liver Disease & NASH Industry Overview

  • 3.1 Overview
    • 3.1.1 Risk Factors for NAFLD & NASH
    • 3.1.2 Diagnosis and Staging of NAFLD/NASH
    • 3.1.3 Imaging Assessment of Steatosis
    • 3.1.4 Liver biopsy for NAFLD
    • 3.1.5 A Pragmatic Approach To Diagnosis And Staging Of NAFLD In Clinical Practice
  • 3.2 COVID-19 Impact of Liver Diseases

4 Market Drivers, Restraints and Opportunities

  • 4.1 Overview
  • 4.2 Increase in number of patients affected by NASH
  • 4.3 Rising Healthcare Expenditure
  • 4.4 Rising Studies And Drugs Developments
  • 4.5 Absence Of Low-Cost And Definitive Diagnostic Methods
  • 4.6 Challenge Due To Regulatory Bodies And Drug Approval
  • 4.7 Porter's Five Forces Analysis
    • 4.7.1 Threat of New Entrants - Low
    • 4.7.2 Bargaining Power of Suppliers - Low
    • 4.7.3 Bargaining Power of Buyers - Moderate
    • 4.7.4 Threat of Substitutes - Moderate to Low
    • 4.7.5 Competitive Rivalry - High

5 Global Non-alcoholic Fatty Liver Disease & NASH Market Analysis

  • 5.1 Global Market Overview
  • 5.2 Global Market Estimation & Forecast
    • 5.2.1 Pre-COVID Market Analysis
    • 5.2.2 Post-COVID Market Analysis (V, W, U, L-Shaped Recovery)
  • 5.3 Regional Market Analysis
    • 5.3.1 Pre-COVID Market Analysis
    • 5.3.2 Market Share Analysis, 2021,2026 & 2031 (%)
    • 5.3.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 5.4 Global Market Breakdown by Disease Cause
    • 5.4.1 Pre-COVID Market Analysis
    • 5.4.2 Market Share Analysis, 2021,2026 & 2031 (%)
    • 5.4.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 5.5 Global Market Breakdown by Drug Type
    • 5.5.1 Pre-COVID Market Analysis
    • 5.5.2 Market Share Analysis, 2021,2026 & 2031 (%)
    • 5.5.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 5.6 Global Market Breakdown by Sales Channel
    • 5.6.1 Pre-COVID Market Analysis
    • 5.6.2 Market Share Analysis, 2021,2026 & 2031 (%)
    • 5.6.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)

6 North America Non-alcoholic Fatty Liver Disease & NASH Market Analysis

  • 6.1 North America Market Overview
  • 6.2 North America Market Estimation & Forecast
    • 6.2.1 Pre-COVID Market Analysis
    • 6.2.2 Post-COVID Market Analysis (V, W, U, L-Shaped Recovery)
  • 6.3 North America Market Breakdown by Country
    • 6.3.1 Pre-COVID Market Analysis
    • 6.3.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 6.4 North America Market Breakdown by Disease Cause
    • 6.4.1 Pre-COVID Market Analysis
    • 6.4.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 6.5 North America Market Breakdown by Drug Type
    • 6.5.1 Pre-COVID Market Analysis
    • 6.5.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 6.6 North America Market Breakdown by Sales Channel
    • 6.6.1 Pre-COVID Market Analysis
    • 6.6.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 6.7 US Non-alcoholic Fatty Liver Disease & NASH Market Analysis
    • 6.7.1 US Market Outlook
    • 6.7.2 Pre-COVID Market Analysis
    • 6.7.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 6.8 Canada Non-alcoholic Fatty Liver Disease & NASH Market Analysis
    • 6.8.1 Canada Market Outlook
    • 6.8.2 Pre-COVID Market Analysis
    • 6.8.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)

7 Europe Non-alcoholic Fatty Liver Disease & NASH Market Analysis

  • 7.1 Europe Market Overview
  • 7.2 Europe Market Estimation & Forecast
    • 7.2.1 Pre-COVID Market Analysis
    • 7.2.2 Post-COVID Market Analysis (V, W, U, L-Shaped Recovery)
  • 7.3 Europe Market Breakdown by Country
    • 7.3.1 Pre-COVID Market Analysis
    • 7.3.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 7.4 Europe Market Breakdown by Disease Cause
    • 7.4.1 Pre-COVID Market Analysis
    • 7.4.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 7.5 Europe Market Breakdown by Drug Type
    • 7.5.1 Pre-COVID Market Analysis
    • 7.5.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 7.6 Europe Market Breakdown by Sales Channel
    • 7.6.1 Pre-COVID Market Analysis
    • 7.6.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 7.7 Germany Non-alcoholic Fatty Liver Disease & NASH Market Analysis
    • 7.7.1 Germany Market Outlook
    • 7.7.2 Pre-COVID Market Analysis
    • 7.7.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 7.8 UK Non-alcoholic Fatty Liver Disease & NASH Market Analysis
    • 7.8.1 UK Market Outlook
    • 7.8.2 Pre-COVID Market Analysis
    • 7.8.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 7.9 France Non-alcoholic Fatty Liver Disease & NASH Market Analysis
    • 7.9.1 France Market Outlook
    • 7.9.2 Pre-COVID Market Analysis
    • 7.9.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 7.10 Italy Non-alcoholic Fatty Liver Disease & NASH Market Analysis
    • 7.10.1 Italy Market Outlook
    • 7.10.2 Pre-COVID Market Analysis
    • 7.10.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 7.11 Spain Non-alcoholic Fatty Liver Disease & NASH Market Analysis
    • 7.11.1 Spain Market Outlook
    • 7.11.2 Pre-COVID Market Analysis
    • 7.11.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 7.12 Rest of Europe Non-alcoholic Fatty Liver Disease & NASH Market Analysis
    • 7.12.1 Rest of Europe Market Outlook
    • 7.12.2 Pre-COVID Market Analysis
    • 7.12.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)

8 Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market Analysis

  • 8.1 Asia-Pacific Market Overview
  • 8.2 Asia-Pacific Market Estimation & Forecast
    • 8.2.1 Pre-COVID Market Analysis
    • 8.2.2 Post-COVID Market Analysis (V, W, U, L-Shaped Recovery)
  • 8.3 Asia-Pacific Market Breakdown by Country
    • 8.3.1 Pre-COVID Market Analysis
    • 8.3.2 Market Share Analysis, 2021,2026 & 2031 (%)
    • 8.3.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 8.4 Asia-Pacific Market Breakdown by Disease Cause
    • 8.4.1 Pre-COVID Market Analysis
    • 8.4.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 8.5 Asia-Pacific Market Breakdown by Drug Type
    • 8.5.1 Pre-COVID Market Analysis
    • 8.5.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 8.6 Asia-Pacific Market Breakdown by Sales Channel
    • 8.6.1 Pre-COVID Market Analysis
    • 8.6.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 8.7 China Non-alcoholic Fatty Liver Disease & NASH Market Analysis
    • 8.7.1 China Market Outlook
    • 8.7.2 Pre-COVID Market Analysis
    • 8.7.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 8.8 India Non-alcoholic Fatty Liver Disease & NASH Market Analysis
    • 8.8.1 India Market Outlook
    • 8.8.2 Pre-COVID Market Analysis
    • 8.8.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 8.9 Japan Non-alcoholic Fatty Liver Disease & NASH Market Analysis
    • 8.9.1 Japan Market Outlook
    • 8.9.2 Pre-COVID Market Analysis
    • 8.9.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 8.10 South Korea Non-alcoholic Fatty Liver Disease & NASH Market Analysis
    • 8.10.1 South Korea Market Outlook
    • 8.10.2 Pre-COVID Market Analysis
    • 8.10.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 8.11 Australia Non-alcoholic Fatty Liver Disease & NASH Market Analysis
    • 8.11.1 Australia Market Outlook
    • 8.11.2 Pre-COVID Market Analysis
    • 8.11.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 8.12 Rest of Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market Analysis
    • 8.12.1 Rest of Asia-Pacific Market Outlook
    • 8.12.2 Pre-COVID Market Analysis
    • 8.12.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)

9 LAMEA Non-alcoholic Fatty Liver Disease & NASH Market Analysis

  • 9.1 LAMEA Market Overview
  • 9.2 LAMEA Market Estimation & Forecast
    • 9.2.1 Pre-COVID Market Analysis
    • 9.2.2 Post-COVID Market Analysis (V, W, U, L-Shaped Recovery)
  • 9.3 LAMEA Market Breakdown by Country
    • 9.3.1 Pre-COVID Market Analysis
    • 9.3.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 9.4 LAMEA Market Breakdown by Disease Cause
    • 9.4.1 Pre-COVID Market Analysis
    • 9.4.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 9.5 LAMEA Market Breakdown by Drug Type
    • 9.5.1 Pre-COVID Market Analysis
    • 9.5.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 9.6 LAMEA Market Breakdown by Sales Channel
    • 9.6.1 Pre-COVID Market Analysis
    • 9.6.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 9.7 Brazil Non-alcoholic Fatty Liver Disease & NASH Market Analysis
    • 9.7.1 Brazil Market Outlook
    • 9.7.2 Pre-COVID Market Analysis
    • 9.7.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 9.8 Saudi Arabia Non-alcoholic Fatty Liver Disease & NASH Market Analysis
    • 9.8.1 Saudi Arabia Market Outlook
    • 9.8.2 Pre-COVID Market Analysis
    • 9.8.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 9.9 South Africa Non-alcoholic Fatty Liver Disease & NASH Market Analysis
    • 9.9.1 South Africa Market Outlook
    • 9.9.2 Pre-COVID Market Analysis
    • 9.9.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 9.10 Mexico Non-alcoholic Fatty Liver Disease & NASH Market Analysis
    • 9.10.1 Mexico Market Outlook
    • 9.10.2 Pre-COVID Market Analysis
    • 9.10.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 9.11 UAE Non-alcoholic Fatty Liver Disease & NASH Market Analysis
    • 9.11.1 UAE Market Outlook
    • 9.11.2 Pre-COVID Market Analysis
    • 9.11.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
  • 9.12 Rest of LAMEA Non-alcoholic Fatty Liver Disease & NASH Market Analysis
    • 9.12.1 Rest of LAMEA Market Outlook
    • 9.12.2 Pre-COVID Market Analysis
    • 9.12.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)

10 Key Company Profiles

  • 10.1 Pfizer Inc Company
    • 10.1.1 Company Snapshot
    • 10.1.2 Company Overview
    • 10.1.3 Company Financial Profile
    • 10.1.4 Company Product Benchmarking
    • 10.1.5 Company Recent Developments
  • 10.2 F. Hoffmann-La Roche Ltd Company
    • 10.2.1 Company Snapshot
    • 10.2.2 Company Overview
    • 10.2.3 Company Financial Profile
    • 10.2.4 Company Product Benchmarking
    • 10.2.5 Company Recent Developments
  • 10.3 Takeda Pharmaceuticals Company
    • 10.3.1 Company Snapshot
    • 10.3.2 Company Overview
    • 10.3.3 Company Financial Profile
    • 10.3.4 Company Product Benchmarking
    • 10.3.5 Company Recent Developments
  • 10.4 Intercept Pharmaceuticals, Inc. Company
    • 10.4.1 Company Snapshot
    • 10.4.2 Company Overview
    • 10.4.3 Company Financial Profile
    • 10.4.4 Company Product Benchmarking
  • 10.5 AstraZeneca Pharmaceuticals Company
    • 10.5.1 Company Snapshot
    • 10.5.2 Company Overview
    • 10.5.3 Company Financial Profile
    • 10.5.4 Company Product Benchmarking
    • 10.5.5 Company Recent Developments
  • 10.6 Novartis Pharmaceutical Company
    • 10.6.1 Company Snapshot
    • 10.6.2 Company Overview
    • 10.6.3 Company Financial Profile
    • 10.6.4 Company Product Benchmarking
    • 10.6.5 Company Recent Developments
  • 10.7 Merck & Co. Company
    • 10.7.1 Company Snapshot
    • 10.7.2 Company Overview
    • 10.7.3 Company Financial Profile
    • 10.7.4 Company Product Benchmarking
    • 10.7.5 Company Recent Developments
  • 10.8 AbbVie Inc Company
    • 10.8.1 Company Snapshot
    • 10.8.2 Company Overview
    • 10.8.3 Company Financial Profile
    • 10.8.4 Company Product Benchmarking
    • 10.8.5 Company Recent Developments
  • 10.9 Gilead Science Inc Company
    • 10.9.1 Company Snapshot
    • 10.9.2 Company Overview
    • 10.9.3 Company Financial Profile
    • 10.9.4 Company Product Benchmarking
    • 10.9.5 Company Recent Developments
  • 10.10 Genfit Biotechnology Company
    • 10.10.1 Company Snapshot
    • 10.10.2 Company Overview
    • 10.10.3 Company Financial Profile
    • 10.10.4 Company Product Benchmarking
    • 10.10.5 Company Recent Developments
  • 10.11 Cardax Inc Pharmaceutical Company
    • 10.11.1 Company Snapshot
    • 10.11.2 Company Overview
    • 10.11.3 Company Financial Profile
    • 10.11.4 Company Product Benchmarking
  • 10.12 Daewoong Co Ltd Company
    • 10.12.1 Company Snapshot
    • 10.12.2 Company Overview
    • 10.12.3 Company Financial Profile
    • 10.12.4 Company Product Benchmarking
    • 10.12.5 Company Recent Developments
  • 10.13 Madrigal Pharmaceuticals, Inc Company
    • 10.13.1 Company Snapshot
    • 10.13.2 Company Overview
    • 10.13.3 Company Product Benchmarking
  • 10.14 Mirum Pharmaceuticals Inc Company
    • 10.14.1 Company Snapshot
    • 10.14.2 Company Overview
    • 10.14.3 Company Recent Developments
  • 10.15 GW Pharmaceuticals Company
    • 10.15.1 Company Snapshot
    • 10.15.2 Company Overview
    • 10.15.3 Company Financial Profile
    • 10.15.4 Company Product Benchmarking
    • 10.15.5 Company Recent Developments

11 Conclusion & Recommendations

  • 11.1.1 Market Share Analysis, 2021,2026 & 2031 (%)

12 Glossary